
- Volume 0 0
FDA ISSUES ALERTS ON ANTIDEPRESSANT AND MIGRAINE DRUGS
The FDA has asked makersof antidepressants tomodify their labels toinclude data about a rarebut life-threatening lungproblem—persistent pulmonary hypertension—that can affect babies born towomen who take the drugs while pregnant.The agency also issued an alertabout the potential risk of combining antidepressantswith common migrainedrugs. The alert warns that a life-threateningcondition called serotonin syndromemay occur when the drugs are combined.
The FDA is investigating additionalinformation on both risks and will issuefurther updates on the drugs' labels asinformation becomes available. "It isimportant to emphasize that the FDArecommends that women who areexpecting and currently taking antidepressantsshould not discontinue usewithout first talking with a doctor," saidSusan Bro, an FDA spokeswoman.
Articles in this issue
almost 20 years ago
Pharmacy Technology Productsalmost 20 years ago
Tobacco Usealmost 20 years ago
Rx Product Newsalmost 20 years ago
OTC Product Newsalmost 20 years ago
can you READ theseRxs?almost 20 years ago
Generic Times Product Newsalmost 20 years ago
compoundingHOTLINEalmost 20 years ago
Compounding for Pediatric Patientsalmost 20 years ago
Vaccinations: Current Research and Perceptionsalmost 20 years ago
Police and Drug Testing





































































































































